Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer

Maurizio Vaglini, Federico Cascinelli, Arturo Chiti, Marcello Deraco, Maria Grazia Inglese, Giacomo Rebuffoni, Maurilia Rizzi, Barbara Sala, Nicola Santoro, Mario Santinami

Research output: Contribution to journalArticlepeer-review


Between May 1990 and December 1995, 16 patients with primary or recurrent unresectable rectal cancer were treated by isolated pelvic perfusion. All patients had been previously treated and were considered unsuitable for surgery or further systemic chemotherapy or radiotherapy. The treatment was based on a perfusion lasting 90 min at 40.5°C with 5-fluorouracil, mitomycin-C and mitoxantrone. Whenever technically feasible (10 cases), continuous intraarterial chemotherapy (through a Medtronic device with a catheter in the inferior mesenteric artery) was administered postoperatively. Two complete responses and 2 partial responses were observed; 8 other patients showed stable disease. One patient did not show any response. Finally, 3 patients for various reasons were not assessable. All patients experienced immediate relief of pain. No major side effects directly related to isolated pelvic perfusion were recorded; a transitory bone marrow depletion was observed in all cases. In conclusion, isolated pelvic perfusion is useful in inoperable disease of the pelvis by reliably relieving pain and thereby improving the patients quality of life.

Original languageEnglish
Pages (from-to)459-462
Number of pages4
Issue number5
Publication statusPublished - Sep 1996


  • hyperthermia
  • pelvic recurrences
  • perfusion
  • rectal cancer
  • regional therapy

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer'. Together they form a unique fingerprint.

Cite this